The NADPH oxidase subunit p22phox inhibits the function of the tumor suppressor protein tuberin

American Journal of Pathology

Volumn 176, Issue 5, 2010, Pages 2447-2455

  Block, Karen ^a,b   Gorin, Yves ^a   New, David D ^a   Eid, Assaad ^a   Chelmicki, Tomasz ^a   Reed, Amanda ^a   Choudhury, Goutam Ghosh ^a,b   Parekh, Dipen J ^a   Abboud, Hanna E ^a,b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE P22 PHOX; S6 KINASE; SMALL INTERFERING RNA; TUBERIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER INHIBITION; DOWN REGULATION; ENZYME SUBUNIT; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; UPREGULATION;

EID: 77952079054     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090606     Document Type: Article

References (38)

1. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr: Inhibition of HIF2a is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003, 3:439-444
2. An J, Rettig MB: Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol 2005, 17:7546-7556
3. Petrella BL, Lohi J, Brinckerhoff CE: Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Oncogene 2005, 24:1043-1052
4. Petrella BL, Brinckerhoff CE: Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase. Mol Cancer 2006, 5:66
5. Suh YA, Arnold RS, Lassegue B, Shi J, Xu X, Sorescu D, Chung AB, Griendling KK, Lambeth JD: Cell transformation by the superoxidegenerating oxidase Mox1. Nature 1999, 401:79-82
6. Arbiser JL, Petros J, Klafter R, Govindajaran B, McLaughlin ER, Brown LF, Cohen C, Moses M, Kilroy S, Arnold RS, Lambeth JD: Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci USA 2002, 99:715-720
7. Brar SS, Kennedy TP, Whorton AR, Sturrock AB, Huecksteadt TP, Ghio AJ, Hoidal JR: Reactive oxygen species from NAD(P)H:quinone oxidoreductase constitutively activate NF-kappaB in malignant melanoma cells. Am J Physiol Cell Physiol 2001, 280:C659-C676
8. Vaquero EC, Edderkaoui M, Pandol SJ, Gukovsky I, Gukovskaya AS: Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells. J Biol Chem 2004, 279:34643-34654 (Pubitemid 39318094)
9. Brar SS, Corbin Z, Kennedy TP, Hemendinger R, Thornton L, Bommarius B, Arnold RS, Whorton AR, Sturrock AB, Huecksteadt TP, Quinn MT, Krenitsky K, Ardie KG, Lambeth JD Hoidal JR: NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells. Am J Physiol Cell Physiol 2003, 285:C353-C369
10. Maranchie JK, Zhan Y: Nox4 is critical for hypoxia-inducible factor 2-a transcriptional activity in von Hippel-Lindau-deficient renal cell carcinoma. Cancer Res 2005, 65:9190-9193
11. Block K, Gorin Y, Hoover P, Williams P, Chelmicki T, Clark RA, Yoneda T, Abboud HE: NAD(P)H oxidases regulate HIF-2a protein expression. J Biol Chem 2007, 282:8019-8026 (Pubitemid 47093603)
12. Sudarshan S, Sourbier C, Kong HS, Block K, Valera Romero VA, Yang Y, Galindo C, Mollapour M, Scroggins B, Goode N, Lee MJ, Gourlay CW, Trepel J, Linehan WM, Neckers L: Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxiainducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol 2009, 29:4080-4090
13. Zhu Y, Marchal CC, Casbon AJ, Stull N, von Löhneysen K, Knaus UG, Jesaitis AJ, McCormick S, Nauseef WM, Dinauer MC. Deletion mutagenesis of p22phox subunit of flavocytochrome b558: identification of regions critical for gp91phox maturation and NADPH oxidase activity. J Biol Chem 2006, 281:30336-30346
14. Kawahara T, Ritsick D, Cheng G, Lambeth JD. Point mutations in the proline-rich region of p22phox are dominant inhibitors of Nox1- and Nox2-dependent reactive oxygen generation. J Biol Chem 2005, 280:31859-31869 (Pubitemid 41291936)
15. Ambasta RK, Kumar P, Griendling KK, Schmidt HH, Busse R, Brandes RP. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J Biol Chem 2004, 279:45935-45941 (Pubitemid 39491586)
16. Bedard K, Krause KH The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007, 87:245-313 (Pubitemid 46209993)
17. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 2002, 10:151-162 (Pubitemid 34876569)
18. Plas DR, Thompson CB: Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem 2003, 14:12361-12366
19. Das F, Ghosh-Choudhury N, Mahimainathan L, Venkatesan B, Feliers D, Riley DJ, Kasinath BS, Choudhury GG: Raptor-rictor axis in TGF-beta-induced protein synthesis. Cell Signal 2008, 20:409-423
20. Block K, Appikonda S, Lin HR, Bloom J, Pagano M, Yew PR. The acidic tail domain of human Cdc34 is required for p27Kip1 ubiquitination and complementation of a cdc34 temperature sensitive yeast strain. Cell Cycle 2005, 4:1421-1427
21. Riemenschneider MJ, Betensky RA, Pasedag SM, Louis DN: AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res 2006, 66:5618-5623
22. Inoki K, Li Y, Zhu T, Wu J, Guan KL: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat Cell Biol 2002, 4:648-657
23. Manning BD, Cantley LC: Rheb fills a GAP between TSC and TOR. Trends Biochem Sci 2003, 2:573-576
24. Gingras AC, Raught B, Sonenberg N: eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999, 68:913-963
25. Heesom KJ, Denton RM: Dissociation of the eukaryotic initiation factor-4E/4E-BP1 complex involves phosphorylation of 4E-BP1 by an mTOR-associated kinase. FEBS Lett 1999, 457:489-493
26. Kwon J, Lee SR, Yang KS, Ahn Y, Kim YJ, Stadtman ER, Rhee SG: Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci USA 2004, 101:16419-16424
27. Seo JH, Ahn Y, Lee SR, Yeol Yeo C, Chung Hur K: The major target of the endogenously generated reactive oxygen species in response to insulin stimulation is phosphatase and tensin homolog and not phosphoinositide-3 kinase (PI-3 kinase) in the PI-3 kinase/Akt pathway. Mol Biol Cell 2005, 16:348-357
28. Sourbier C, Lindner V, Lang H, Agouni A, Schordan E, Danilin S, Rothhut S, Jacqmin D, Helwig JJ, Massfelder T: The phosphoinosititde 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res 2006, 66:5130-5142
29. Petrella B, Brinckerhoff CE: PTEN suppression of YY1 induces HIF-2a activity in von Hippel Lindau null renal cell carcinoma. Cancer Biol Ther 2009, 8:1-13
30. Brandes RP, Schröder K: Differential vascular functions of Nox family NADPH oxidases. Curr Opin Lipidol 2008, 19:513-518
31. Blanchetot C, Boonstra J: The ROS-NOX connection in cancer and angiogenesis. Crit Rev Eukaryot Gene Expr 2008, 18:35-45
32. Ushio-Fukai M, Nakamura Y: Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 2008, 266:37-52
33. Goyal P, Weissmann N, Grimminger F, Hegel C, Bader L, Rose F, Fink L, Ghofrani HA, Schermuly RT, Schmidt HH, Seeger W, Hanze J: Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxiainducible factor 1 via increase in reactive oxygen species. Free Radic Biol Med 2004, 36:1279-1288
34. Mittal M, Roth M, König P, Hofmann S, Dony E, Goyal P, Selbitz AC, Schermuly RT, Ghofrani HA, Kwapiszewska G, Kummer W, Klepetko W, Hoda MA, Fink L, Hanze J, Seeger W, Grimminger F, Schmidt HH, Weissmann N: Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res 2007, 101:258-267
35. Li S, Tabar SS, Malec V, Eul BG, Klepetko W, Weissmann N, Grimminger F, Seeger W, Rose F, Hanze J: NOX4 regulates ROS levels under normoxic and hypoxic conditions, triggers proliferation, and inhibits apoptosis in pulmonary artery adventitial fibroblasts. Antioxid Redox Signal 2008, 10:1687-1698
36. Parry L, Maynard JH, Patel A, Clifford SC, Morrissey C, Maher ER, Cheadle JP, Sampson JR: Analysis of the TSC1 and TSC2 genes in sporadic renal cell carcinomas. Br J Cancer 2001, 8:1226-1230
37. Duffy K, Al-Saleem T, Karbowniczek M, Ewalt D, Prowse AH, Henske EP: Mutational analysis of the von Hippel Lindau gene in clear cell renal carcinomas from tuberous sclerosis complex patients. Mod Pathol 2002, 3:205-210
38. Liu MY, Poellinger L, Walker CL: Up-regulation of hypoxia-inducible factor 2a in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Cancer Res 2003, 10:2675-2680